Belgian Electronic Equipment and Components Stock News

Agfa-Gevaert (ENXTBR:AGFB) just released its third quarter and nine-month 2025 earnings results. The report shows that sales have dipped and net losses have widened this quarter compared to the same period last year. See our latest analysis for Agfa-Gevaert. Agfa-Gevaert’s latest trading has been turbulent, with the share price dropping sharply by 20% over the past week and now sitting at $0.625. Looking at the bigger picture, momentum is clearly weak, as the 1-year total shareholder return...

Viohalco S.A. ( EBR:VIO ) shares have continued their recent momentum with a 31% gain in the last month alone. The last...

When close to half the companies in Belgium have price-to-earnings ratios (or "P/E's") above 15x, you may consider DEME...

Agfa-Gevaert NV recently reported its third quarter 2025 earnings, revealing sales of €257 million and a net loss of €19 million, both down compared to the same period last year. Although the company's nine-month net loss improved versus the previous year, the quarterly results point to continued operational headwinds affecting Agfa-Gevaert's performance. We'll explore how the combination of declining quarterly sales and a widening net loss is shaping Agfa-Gevaert's investment narrative. AI...

Earlier this month, Barco announced the expansion of its strategic ClickShare partnerships with Sennheiser, Logitech, and Huddly, aiming to deliver integrated, high-performance meeting room solutions through certified room system bundles built around the new ClickShare Hub. This collaboration leverages advanced audio and video technologies to strengthen Barco's position in the wireless BYOD and meeting room systems market, facilitating broader adoption of its solutions in diverse meeting...

NV Bekaert (ENXTBR:BEKB) just announced a partnership with EMSTEEL to develop sustainable steel products and solutions using UAE-made steel. The collaboration covers technical cooperation and aims to expand offerings across Gulf markets. See our latest analysis for NV Bekaert. Bekaert’s recent partnership news comes after a steady period for its stock, with year-to-date share price gains of 3.57% and a solid 12.82% total shareholder return over the past year. Despite some short-term...

Cenergy Holdings reported third-quarter and nine-month 2025 results, delivering sales of €524.27 million and €1.55 billion, and net income of €52.43 million and €147.69 million, respectively, both up from the prior year. Sales and net income growth outpaced the previous year's comparable periods, suggesting the company's operations benefited from strong demand and improved profitability. We'll take a closer look at how Cenergy Holdings' strong revenue and earnings growth this quarter informs...

While D'Ieteren Group SA ( EBR:DIE ) shareholders are probably generally happy, the stock hasn't had particularly good...

Belgian holding company GBL recently sold half its stake in Umicore through an accelerated bookbuild, reducing its ownership from 16% to 8% and committing to a 90-day lock-up on its remaining shares. This transaction reflects GBL’s broader plan to streamline its portfolio towards private assets and follows a period of recovery for Umicore’s share price. We'll assess how GBL's sizable stake reduction impacts Umicore’s investment outlook and potential capital structure considerations going...

Azelis Group (ENXTBR:AZE) shares have recently caught the attention of market watchers, with moves in the stock price reflecting a broader pattern in the specialty chemicals sector. Trading activity suggests investors are weighing up the company’s most recent business fundamentals. See our latest analysis for Azelis Group. Azelis Group’s 1-year total shareholder return of -48.71% reflects a tough stretch for the business, with momentum clearly fading as the stock’s YTD share price return sits...

argenx (ENXTBR:ARGX) stock has gained fresh attention from investors recently, and its movement stands out when you look at how it has performed over the past month and past 3 months. The company’s trajectory offers some interesting discussion points for those interested in the biotech sector. See our latest analysis for argenx. argenx has captured attention with a 40% 90-day share price return and a strong 48% total shareholder return over the last year, reflecting renewed investor optimism...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Key Insights The projected fair value for Melexis is €54.64 based on 2 Stage Free Cash Flow to Equity With €55.65 share...

KBC Group NV reported third quarter and nine-month earnings for the period ended September 30, 2025, with net income rising to €1.00 billion for the quarter and €2.57 billion for the nine months, both higher than the same periods last year. The company's earnings per share from continuing operations also increased over both periods, reflecting improved profitability and operational performance. We'll assess how the jump in net income and earnings per share informs KBC Group's ongoing...

Noveon Magnetics and Solvay recently announced a multi-year supply agreement for light and heavy rare earth oxides, with Solvay providing Neodymium-Praseodymium, Dysprosium, and Terbium oxides, sourced partly from recycled materials, to support Noveon's production of permanent magnets starting in 2026. This collaboration advances a more resilient and sustainable domestic supply chain for rare earth magnets amid ongoing global supply risks and growing demand. The agreement enhances Solvay's...

argenx SE recently received Health Canada approval for VYVGART SC as a monotherapy for adult patients with active chronic inflammatory demyelinating polyneuropathy (CIDP), making it the first innovative CIDP treatment option in Canada in over 30 years and the first FcRn blocker approved for this use. The once-weekly, subcutaneous self-administration of VYVGART SC presents a new level of flexibility and convenience for patients while potentially reducing demand for human-derived blood...

Campine NV ( EBR:CAMB ) shares have had a horrible month, losing 26% after a relatively good period beforehand. Of...

It's not a stretch to say that Azelis Group NV's ( EBR:AZE ) price-to-earnings (or "P/E") ratio of 14x right now seems...

UCB (ENXTBR:UCB) received FDA approval for KYGEVVI, marking a major step in rare disease treatment. KYGEVVI is the first approved therapy for TK2d, a life-threatening mitochondrial disorder with very limited options. See our latest analysis for UCB. Following the FDA approval for KYGEVVI, UCB's momentum has been building. The share price has climbed nearly 20% year-to-date. After some short-term volatility, the stock's 1-year total shareholder return stands at an impressive 26%. Those who...

Syensqo reported third quarter 2025 earnings, revealing sales of €1.56 billion and net income of €39 million, compared to a third quarter net loss in 2024, despite a year-on-year decline in revenue for both the quarter and nine months ending September 30. The company’s rebound to profitability in the third quarter, following a loss a year earlier, underscores a shift in its performance trend even amid lower sales. We’ll assess how Syensqo’s return to quarterly profit, despite weaker sales,...

UCB announced that KYGEVVI, a combination therapy for thymidine kinase 2 deficiency (TK2d), has received approval from the U.S. FDA, making it the first and only approved treatment for this ultra-rare, life-threatening mitochondrial disorder in both adults and pediatric patients with symptom onset before age 12. This approval provides UCB with entry into a new therapeutic area with high unmet need, and comes with a Rare Pediatric Disease Priority Review Voucher from the FDA, highlighting...

Lotus Bakeries was recently added to the Euronext 150 Index, highlighting its growing profile among Europe’s largest listed companies. This milestone can influence share demand as index-tracking funds and institutional investors may adjust holdings to include the company. We’ll now explore how inclusion in a major index could impact Lotus Bakeries’ investment narrative and future institutional interest. AI is about to change healthcare. These 32 stocks are working on everything from early...

This week we saw the Banqup Group SA ( EBR:BANQ ) share price climb by 11%. But that doesn't change the fact that the...

Anheuser-Busch InBev announced a US$6 billion share repurchase program and released its third quarter 2025 earnings, reporting sales of US$15.13 billion and net income of US$1.05 billion for the quarter ended September 30, 2025. The board also approved an interim dividend, renewed a key services framework with its Asia-Pacific subsidiary, and disclosed the upcoming departure of its longstanding Chief People Officer, marking a period of significant corporate actions. We'll explore how the...